David Geffen School of Medicine, University of California Los Angeles (R.A.M., J.S., K.T.M., K.M., C.T., M.T., D.S.L., J.D.H.).
Glenn Biggs Institute for Alzheimer's & Neurodegenerative Diseases (C.D.W., R.B., J.J.H., S.S.), University of Texas Health Science Center at San Antonio.
Stroke. 2024 Jun;55(6):1601-1608. doi: 10.1161/STROKEAHA.123.044719. Epub 2024 May 1.
A coordinated network of circulating inflammatory molecules centered on the pleotropic pro-atherogenic cytokine interleukin-18 (IL-18) is linked to cerebral small vessel disease. We sought to validate the association of this inflammatory biomarker network with incident stroke risk, cognitive impairment, and imaging metrics in a sample of the Framingham Offspring Cohort.
Using available baseline measurements of serum levels of IL-18, GDF (growth and differentiation factor)-15, soluble form of receptor for advanced glycation end products, myeloperoxidase, and MCP-1 (monocyte chemoattractant protein-1) from Exam 7 of the Framingham Offspring Cohort (1998-2001), we constructed a population-normalized, equally weighted log-transformed mean -score value representing the average level of each serum analyte to create an inflammatory composite score (ICS5). Multivariable regression models were used to determine the association of ICS5 with incident stroke, brain magnetic resonance imaging features, and cognitive testing performance.
We found a significant association between ICS5 score and increased risk for incident all-cause stroke (hazard ratio, 1.48 [95% CI, 1.05-2.08]; =0.024) and ischemic stroke (hazard ratio, 1.51 [95% CI, 1.03-2.21]; =0.033) in the Exam 7 cohort of 2201 subjects (mean age 62±9 years; 54% female) aged 45+ years with an all-cause incident stroke rate of 6.1% (135/2201) and ischemic stroke rate of 4.9% (108/2201). ICS5 and its component serum markers are all associated with the Framingham Stroke Risk Profile score (β±SE, 0.19±0.02; <0.0001). In addition, we found a significant inverse association of ICS5 with a global cognitive score, derived from a principal components analysis of the neuropsychological battery used in the Framingham cohort (-0.08±0.03; =0.019). No association of ICS5 with magnetic resonance imaging metrics of cerebral small vessel disease was observed.
Circulating serum levels of inflammatory biomarkers centered on IL-18 are associated with an increased risk of stroke and cognitive impairment in the Framingham Offspring Cohort. Linking specific inflammatory pathways to cerebral small vessel disease may enhance individualized quantitative risk assessment for future stroke and vascular cognitive impairment.
以多效促动脉粥样硬化细胞因子白细胞介素-18(IL-18)为中心的循环炎症分子协调网络与脑小血管疾病有关。我们试图在弗雷明汉后代队列的样本中验证该炎症生物标志物网络与卒中事件风险、认知障碍和影像学指标的关联。
利用弗雷明汉后代队列第 7 次检查(1998-2001 年)中血清 IL-18、GDF(生长分化因子)-15、晚期糖基化终产物受体可溶性形式、髓过氧化物酶和单核细胞趋化蛋白-1(MCP-1)的基线测量值,我们构建了一个人群归一化、等权重对数转换的平均 - 分数值,代表每个血清分析物的平均水平,以创建炎症综合评分(ICS5)。多变量回归模型用于确定 ICS5 与卒中事件、脑磁共振成像特征和认知测试表现的关联。
我们发现 ICS5 评分与全因卒中(危险比,1.48 [95%CI,1.05-2.08];=0.024)和缺血性卒中(危险比,1.51 [95%CI,1.03-2.21];=0.033)的风险增加显著相关,在弗雷明汉后代队列的 2201 名受试者(平均年龄 62±9 岁;54%为女性)中,年龄 45+岁,全因卒中发生率为 6.1%(135/2201),缺血性卒中发生率为 4.9%(108/2201)。ICS5 及其组成血清标志物均与弗雷明汉卒中风险评分相关(β±SE,0.19±0.02;<0.0001)。此外,我们发现 ICS5 与基于弗雷明汉队列中神经心理学电池的主成分分析得出的全球认知评分呈显著负相关(-0.08±0.03;=0.019)。未观察到 ICS5 与脑小血管疾病的磁共振成像指标之间存在关联。
以白细胞介素-18 为中心的循环血清炎症标志物水平与弗雷明汉后代队列中卒中风险和认知障碍的增加相关。将特定的炎症途径与脑小血管疾病联系起来,可能会增强对未来卒中和血管性认知障碍的个体化定量风险评估。